Physician profile
Robert H Gross
NPI 1689623365
$3,470.30
in general payments reported to CMS, 2019-2025
22 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $1,429 · 2021: $187 · 2022: $207 · 2023: $413 · 2024: $317 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.30 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $1,385.40 | 2019-2020 | |
| Dompe US, INC. | $544.60 | 2019-2025 | Oxervate |
| Rxsight INC | $361.31 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $282.80 | 2019-2023 | |
| Alcon Vision LLC | $151.71 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $106.32 | 2020 | |
| Apellis Pharmaceuticals, INC. | $98.66 | 2025 | Syfovre |
| Genentech USA, INC. | $81.04 | 2022 | |
| Harrow Eye, LLC | $78.38 | 2025 | Vevye |
| Kowa Research Institute, INC. | $73.48 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $44.83 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $40.40 | 2022-2023 | Miebo |
| Biotissue Holdings INC. | $40.04 | 2021-2025 | |
| Oyster Point Pharma, INC. | $32.55 | 2025 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $31.24 | 2024 | Rayone Aspheric, Rayone Spheric, Omidria |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $22.67 | 2019 | |
| Ocular Therapeutix, INC. | $22.59 | 2020 | |
| Eyepoint US, INC. | $21.38 | 2019 | |
| Kala Pharmaceuticals, INC. | $18.75 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $17.13 | 2023 | Tecnis Iol, Tecnis Iol |
| Sight Sciences, INC. | $15.02 | 2023 | Tearcare System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.